||COM STK USD0.01 (DI)
||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Maxcyte (DI) Share Discussion Threads
Showing 51 to 75 of 75 messages
|I believe the offer was substantially over subscribed Tim!|
|I wasn't offered any this time around but would have passed anyway given the eventual placing price.
It's quite unusual to get a big placing away at a premium, especially on AIM !|
|Good luck Tim!|
|The proposed placing is for all the right reasons, I wonder what price they will get it away at and will any of it qualify for EIS?
If I am given the opportunity to invest again I may have small nibble depending on the price and assuming the shares are issued in the next tax year and they qualify for EIS tax relief.|
|I think you could be right Tim, the question is at what price!|
|Both Doug Doerfler (CEO) and Ron Holtz (CFO) were at the Proactive event on Thursday, unfortunately there was no hard copy of the slides to take away and there isn't a soft copy (yet) on the Proactive site, but I will request a copy and scribble a few notes tomorrow. I can see now why they are capitalised at >£100m and I really do not think they will be around as an independent company in 5 years time, somebody will take them out.|
|Maxcyte CEO Doug Doerfler will be presenting to investors at the upcoming Proactive One2One Forum taking place on the evening of 23rd March in Mayfair, London. For details and registration, please click here: https://tinyurl.com/zupvh3j|
|I thought they might go a bit higher today on the back of that news, so I'll save the the next rocket for a better day, meanwhile there's a new interview with Doug Doerfler on Proactive investor which is well worth a listen:
in response to a question on why do they (i.e. big biotech) come to MaxCyte? DD states in his response:
.......we can deliver any molecule to any cell at any scale and we do it highly efficiently, high performance and we also do it in a clinical setting so it can be used to modify those cells to engineer cells and return those cells to the patient and we are the only group who can do that clinically......"
Which goes some way to explain why the shares are in such demand|
|Time for another Rocket video clip Tim?|
|New Trinity Delta Research note now out following today's announcement:
|MaxCyte will be presenting at the Proactive investor evening on Thursday March 23rd, I plan to attend and will report back in due course:
I find it impossible to value this one, I bought primarily for the tax breaks as you know. I dont really believe in reading tea leaves, but I suspect the chartists would have said it was overdue a big correction at 280p, mind you they would probably have told you the same thing at 140p and 210p on the way up (and it didnt happen). This is one share where I havent been able to talk to the ,management, so all I have to go on is what is in the public domain.
The Trinity Development research notes are a useful read if you haven't already seen them
you probably have studied this one thoroughly- i have been watching it and i notice it is down 30pc- but no clue as to whether this presents an opportunity to enter? just interested in your take!|
|Let sleeping dogs lie timbo003!|
|This is now a 4 bagger since the IPO, or a 5.5 bagger if you take into account the EIS tax relief.
I find it quite extraordinary that there is no interest here. I would have thought at least the Scancell crowd might have had a sniff around, given that MaxCyte's business is all about Electroporation and Scancell's lead drug (SCIB1) requires electroporation for effective delivery.|
|Here's a date for your diaries
23rd March MaxCyte will be presenting at the Proactiveinvestor evening at the Chesterfield Hotel in Mayfair,
It's free and you get fed and watered afterwards, so I've booked my place.
|Another good day, market cap now just a tad over £100m, presumably it will now get on a few more radar screens.|
|Thanks for that dave4p, there is also a new note available from Trinity Delta here:
|The publication referred to in today's RNS appears to concern the work referred to in Panmure Gordon's morning note from last week.
Up again today, now 3X the IPO price, or over 4X the price paid by IPO participants who qualified for EIS tax reliefs (i.e. 49p/share).|
|Yes and from memory 50+ licencees,(up from 30+ at the time of the float).|
That note from Panmure puts the rise into context, so they are now looking at a new platform which is likely to be of considerable interest to big pharma and it sounds like Maxcyte are the only shop in town|
|And the following update by PG:
|The Ft has named it as the top pharma small cap stock pick of 2017.|